Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the\xa0ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients have\xa0been found to be\xa0associated with overexpression of ACE2.To decrease the severity of COVID-19 infection ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision. Important Steps to Control COVID-19/SARS-CoV-2 Infection.